Zealand Pharma A/s · OMXCOP:ZEAL
Zealand Pharma A/s — FY2023 Earnings Presentation
16 slides from Zealand Pharma A/s's earnings presentation, Feb 27, 2024
Slide 1: 2023 Annual Report
2023 Annual Report Zealand Pharma February 27, 2024
Slide 2: Forward-looking Statements
Forward-looking Statements This presentation contains “forward-looking statements”, as that term is defined in the Private Securities Litigation Reform Act of 1995 in the United States, as amended, even though no longer listed in the United States this is used as a definition to provide Zealand Phar
Slide 3: About ZP: In 2023 we delivered key strategic objectives
About ZP In 2023 we delivered key strategic objectives Advanced differentiated obesity portfolio Progressed rare disease assets to patients Dasiglucagon in congenital hyperinsulinism Petrelintide • 6-week trial results at amylin analog ObesityWeek • NDA submitted in June 2023 • 16-week trial of high
Slide 4: In 2024 we are expanding efforts to advance our pipeline of differentiated obesity assets
About ZP In 2024 we are expanding efforts to advance our pipeline of differentiated obesity assets Petrelintide Dapiglutide Survodutide2 (amylin analog) (GLP-1R/GLP-2R) (GCGR/GLP-1R) Ph1b 16-week MAD clinical trial Ph2a DREAM clinical trial data1 data Ph2 MASH clinical trial data Ph2b trial initiati
Slide 5: Our R&D pipeline addresses unmet medical needs across several therapeutic areas
Our R&D pipeline addresses unmet medical needs across several therapeutic areas Product candidatea Partnered Pre-clinical Phase 1 Phase 2 Phase 3 Registration , Dapiglutide (GLP-1R/GLP-2R dual agonist) Obesity Obesity Petrelintide (amylin analog) Obesity ZP6590 (GIP receptor agonist) Obesity Survodu
Slide 6: Petrelintide offers potential for significant weight loss
Obesity Petrelintide Petrelintide offers potential for significant weight loss: achieved average weight loss of >5% in MAD Part 1 of the Phase 1b MAD trial of petrelintide A potentially best-in-class amylin analog 5 Targeting GLP-1-like weight reduction; high quality Change in body weight (%) Placeb
Slide 7: Dapiglutide showed dose-dependent mean weight loss of up to 4.3% over 4 weeks
Dapiglutide Obesity Dapiglutide Dapiglutide showed dose-dependent mean weight loss of up to 4.3% over 4 weeks in healthy patients Phase 1 multiple ascending dose trial (n=40) A first-in-class GLP-1R/GLP-2R 2 Safety and tolerability similar to other GLP-1- based weight-loss medications Change in body
Slide 8: Survodutide shows best-in-class potential in MASH Phase 2 trial
Obesity/MASH Survodutide Survodutide* GCGR/GLP-1 receptor dual agonist shows best-in-class potential in MASH Phase 2 trial Phase 2 trial in people with overweight or obesity1 Phase 2 biopsy-driven trial in people with MASH3 Mean relative change at Week 46 (%) Participants showing improvement in MASH
Slide 9: Dasiglucagon is being developed to address a high unmet need for the management of CHI
Rare diseases CHI Dasiglucagon is being developed to address a high unmet need for the management of CHI Submissions to support regulatory decisions in 2024 Two Phase 3 trials in neonates and children up to 12 years of age demonstrated clinical potential Resubmission of NDA Part 1 for up to three we
Slide 10: Glepaglutide has best-in-class potential as a next-generation GLP-2 therapy for patients with SBS
Rare diseases SBS Glepaglutide has best-in-class potential as a next- generation GLP-2 therapy for patients with SBS Submission to support regulatory decision in 2024 Significantly reduced weekly PS volume at 24 weeks versus placebo in the EASE-1 trial in SBS1 Expected 10 mg twice-weekly subcutaneou
Slide 11: 2023 FY Profit & Loss
2023 FY Profit & Loss DKK million 2023 FY 2022 FY P&L reflecting Zealand’s investment in its differentiated assets targeting obesity Revenue 342.8 104.0 • Revenue of DKK 343 million is driven by milestones from Boehringer Ingelheim for Gross profit 323.6 104.0 survodutide and Sanofi for lixisenatide
Slide 12: Solid cash position allows for investments in R&D
Solid cash position allows for investments in R&D DKK 4.1 billion cash position including January 2024 capital raise, RCF and EIB loan facilities1 4.104 DKK million 1.450 671 1.633 350 1.178 1.500 -1,045 Cash position Change in cash2 Apr-23 Cash position Revolving European Jan-24 Cash position Dec-2
Slide 13: 2024 financial guidance
2024 financial guidance DKK million 2024 2023 Guidance Actual Revenue anticipated from existing and new license and No guidance 343 partnership agreements due to uncertain size and timing Net operating expenses1 1,100 – 1,200 896 Notes 1. Net operating expenses consist of R&D, S&M, G&A and other ope
Slide 14: ESG – Our impact
ESG – Our impact Our patients. Our people. Our operations. • We leverage innovation to advance • We foster an engaging and • We take responsibility for the the health and well-being of patients enriching workplace impact of our operations 76% 253 100% of OPEX allocated to R&D Sustainable energy sour
Slide 15: Significant events and potential catalysts in 2024
Significant events and potential catalysts in 2024 NON-EXHAUSTIVE H1 2024 H2 2024 Petrelintide Petrelintide Topline results from 16-week Phase 1b MAD trial Initiate Phase 2b trial Dapiglutide Dapiglutide Topline results from Phase 2a investigator-initiated trial DREAM Topline results from 13-week Ph
Slide 16: Q&A
Q&A• FY 2023 presentation February 27, 2024 16